100704-10-7

Basic information

• Product Name: (2-CHLORO-PYRIDIN-4-YL)-METHANOL
• Synonyms: (2-CHLORO-PYRIDIN-4-YL)-METHANOL;(2-CHLORO-PYRIDINE-4-YL)-METHANOL;2-CHLORO-4-HYDROXYMETHYLPYRIDINE;(2-CHLORO-4-PYRIDINYL)METHANOL;BUTTPARK 154\50-15;2-Chloro-4-(hydroxymethyl)pyridine 97%;4-Pyridinemethanol,2-chloro-(6CI,9CI);2-Chloro-4-pyridinemethanol
• CAS NO: 100704-10-7
• Molecular Formula: C₆H₆ClNO
• Molecular Weight: 143.57
• EINECS: -0
• Product Categories: PYRIDINE;pharmacetical;Pyridines
• Mol File: 100704-10-7.mol

Chemical Properties

• Melting Point: 65.5 °C
• Boiling Point: 279 °C at 760 mmHg
• Flash Point: 122.5 °C
• Appearance: /
• Density: 1.324 g/cm³
• Vapor Pressure: 0.0264mmHg at 25°C
• Refractive Index: 1.583
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility: soluble in Methanol
• PKA: 13.08±0.10(Predicted)
• CAS DataBase Reference: (2-CHLORO-PYRIDIN-4-YL)-METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: (2-CHLORO-PYRIDIN-4-YL)-METHANOL(100704-10-7)
• EPA Substance Registry System: (2-CHLORO-PYRIDIN-4-YL)-METHANOL(100704-10-7)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22-36/37/38
• Safety Statements: 26-28-45
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 100704-10-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(2-Chloro-pyridin-4-yl)-methanol is used as a pharmaceutical intermediate for the synthesis of various drugs. Its unique structure allows for the creation of diverse chemical structures, making it a valuable reagent in organic synthesis for drug development.
Used in Agrochemical Industry:
In the agrochemical industry, (2-Chloro-pyridin-4-yl)-methanol is used in the production of herbicides and insecticides. Its chlorinated pyridine structure contributes to the effectiveness of these agricultural chemicals in controlling pests and unwanted plant growth.
Used in Specialty Chemicals Production:
(2-Chloro-pyridin-4-yl)-methanol is also utilized in the synthesis of other specialty chemicals. Its versatility and reactivity make it a valuable component in the development of new and innovative chemical products.

InChI:InChI=1/C7H8INO/c1-2-10-7-6(8)4-3-5-9-7/h3-5H,2H2,1H3

Upstream product

• 65287-34-5 2-chloropyridine-4-carbonyl chloride 
• 58481-11-1 methyl 2-chloroisonicotinate 
• 64-17-5 ethanol 
• 54453-93-9 ethyl 2-chloroisonicotinate 
• 6313-54-8 2-chloroisonicotinic acid, 
• 584-08-7 potassium carbonate 
• 151477-57-5 α,α,2-trichloro-4-picoline 
• 67-56-1 methanol 
• 116570-79-7 N-methoxy-2-chloropyridinium methylsulfate 
• 925-90-6 ethylmagnesium bromide 
• 101066-61-9 2-chloropyridine-4-carbaldehyde 

Downstream Products

• 123148-66-3 2-methoxy-4-(hydroxymethyl)-pyridine 
• 329794-09-4 4-({[tert-butyl(dimethyl)silyl]oxy}methyl)pyridin-2-amine 
• 329794-12-9 (4-chloromethylpyridin-2-yl)(5-phenylthiazol-2-yl)amine 
• 329794-11-8 [2-(5-phenylthiazol-2-ylamino)pyridin-4-yl]methanol 
• 329794-10-7 [4-(tert-butyldimethylsilanyloxymethyl)pyridin-2-yl](5-phenylthiazol-2-yl)amine 
• 478962-96-8 C₅₃H₅₁ClN₆O₁₁ 
• 193002-33-4 4-hydroxymethyl-2-(dimethylamino)pyridine 
• 193001-42-2 (2-(methylamino)pyridin-4-yl)methanol 
• 680569-47-5 (2-chloropyridin-4-yl)methyl methanesulphonate 
• 83004-15-3 4-(bromomethyl)-2-chloropyridine 
• 101990-73-2 2-chloro-pyridin-4-ylmethyl chloride 
• 101066-61-9 2-chloropyridine-4-carbaldehyde 
• 1034309-32-4 4-(tert-butyldiphenylsilanyloxymethyl)-2-chloropyridine 
• 1105691-50-6 2-chloro-4-(phenoxymethyl)pyridine 

Relevant articles and documents

Inactivation of O6-alkylguanine-DNA alkyltransferase. 1. Novel O6-(hetarylmethyl)guanines having basic rings in the side chain.

A number of novel guanine derivatives containing heterocyclic moieties at the O6-position have been synthesized using a purine quaternary salt which reacts with alkoxides under mild conditions. Initially O6-substituents were investigated in which the benzene ring of the known agent, O6-benzylguanine, was replaced by unsubstituted heterocyclic rings. The ability of these agents to inactivate the DNA repair protein O6-alkylguanine-DNA alkyltransferase (ATase), both as pure recombinant protein and in the human lymphoblastoid cell line Raji, has been compared with that of O6-benzylguanine. The present paper focuses on O6-substituents with basic rings, and under standard conditions several of them proved more effective than benzyl for inactivation of both recombinant and Raji ATase. Among the pyridine derivatives, the 2-picolyl compound 7 is not very active in contrast to the 3- and 4-picolyl compounds, and this influenced our choice of isomers of other basic ring systems for study. Since halogen substitution in the thiophene ring considerably increased the activity (17 versus 6), similar modifications in the pyridine series were examined. The more polar O6-substituents in this study are on the whole compatible with the stereochemical requirements of the ATase protein, and their pharmacological properties may be valuable in subsequent in vivo investigations, particularly the thenyl (6), 5-thiazolylmethyl (12), 5-bromothenyl (17), and 2-chloro-4-picolyl (21) derivatives.

Photochemical C-H Silylation and Hydroxymethylation of Pyridines and Related Structures: Synthetic Scope and Mechanisms

Considering the synthetic relevance of heteroarenes in various areas ranging from organic synthesis to medicinal chemistry, developing practically simple methodologies to access functionalized heteroarenes is of a significant value. Described herein is an efficient approach for C-H silylation and hydroxymethylation of pyridines and related heterocycles by the combination of silanes or methanol with readily available N-methoxypyridinium ions with a low catalyst loading (2 mol %) under blue light irradiation. The synthetic importance of the developed reactions is demonstrated by the synthesis of biologically relevant compounds. Electron paramagnetic resonance spectroscopy, quantum yield measurements, and density-functional theory calculations allowed us to understand reaction mechanisms of both photocatalytic reactions.

BICYCLIC PROLINE COMPOUNDS

The invention is concerned with the compounds of formula (I) and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

NOVEL BICYCLIC HETEROCYCLIC COMPOUND

Provided are a novel compound having a superior inhibitory action on KAT-II, a production method thereof, use thereof, and a pharmaceutical composition containing the aforementioned compound and the like. A compound represented by the formula (I) or a pharmacologically acceptable salt thereof. wherein each symbol is as defined in the DESCRIPTION.

NAPHTHYRIDINES AS INHIBITORS OF HPK1

Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.

FLUOROINDOLE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention relates to compound of formula (I), or stereoisomers and pharmaceutically acceptable salts as muscarinic M1 receptor positive allosteric modulators. This invention also relates to methods of making such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to muscarinic M1 receptor.(Formula I) (I)

1-(HET)ARYLSULFONYL-(PYRROLIDINE OR PIPERIDINE)-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS

The invention is concerned with the compounds of formula I and salts thereof and other compounds of formulas II-IX as disclosed herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formulas I-IX as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain or asthma.

INHIBITORS OF HEPATITIS C VIRUS POLYMERASE

The present invention provides, among other things, compounds represented by the general Formula I: (I) and pharmaceutically acceptable salts thereof, wherein L and A (and further substituents) are as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection.

8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE

Disclosed is a compound represented by formula (1) or a pharmacologically acceptable salt thereof (In the formula, A represents a group that is represented by formula (A-1); R1a and R1b may be the same or different and each independently represents a C1-6 alkyl group which may be substituted by one to three halogen atoms; m and n each independently represents an integer of 0-5; X1 represents a hydroxyl group or an aminocarbonyl group; Z1 represents a single bond or the like; and R2 represents an optionally substituted C1-6 alkyl group, an optionally substituted C6-10 aryl group or the like.)

HETEROCYCLYL-PYRIDINYL-BASED BIPHOSPHONIC ACID, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF

The present invention relates to novel compounds, compositions containing said compounds and methods for inhibiting human farnesyl pyrophosphate synthase or for the treatment or prevention of disease conditions using said compounds, which may also be useful in the inhibition of FPPS enzymes of microorganisms and protozoan parasites such as the groups of Leishmania, Plasmodium, Trypanosoma, Toxoplasma and Cryptosporidium